Who owns Cullinan Therapeutics, Inc.?
Institutional ownership of CGEM from SEC Form 13F filings across 127 reporting managers. All positions are from one synchronized reporting period — 2026-06-30 books, filed up to 45 days after quarter end — so every row is comparable.
127
13F holders
$432.0M
value, 2026 filers
44.9%
of shares outstanding (27.6M sh)
23
new positions (2026 filers)
Top institutional holders
ordered by shares owned · positions as of 2026-06-30· % of fund = share of the manager's own book · % of co. = share of CGEM's shares outstanding
| # | Manager | Shares | Value | % of fund | % of co. | Δ shares QoQ |
|---|---|---|---|---|---|---|
| 1 | BlackRock, Inc. | 5.2M | $95.3M | 0.0% | 8.5% | +17.6% |
| 2 | PRICE T ROWE ASSOCIATES INC /MD/ | 3.8M | $69,672 | 0.0% | 6.2% | +88.5% |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 2.6M | $47.6M | 0.0% | 4.3% | -47.4% |
| 4 | GEODE CAPITAL MANAGEMENT, LLC | 1.5M | $28.2M | 0.0% | 2.5% | +13.1% |
| 5 | Blue Owl Capital Holdings LP | 1.5M | $28.0M | 4.2% | 2.5% | -19.4% |
| 6 | BOOTHBAY FUND MANAGEMENT, LLC | 1.1M | $19.7M | 0.3% | 1.8% | -2.7% |
| 7 | GOLDMAN SACHS GROUP INC | 1.0M | $18.2M | 0.0% | 1.6% | +119.9% |
| 8 | VANGUARD PORTFOLIO MANAGEMENT LLC | 738,741 | $13.5M | 0.0% | 1.2% | +33.7% |
| 9 | MORGAN STANLEY | 629,035 | $11.5M | 0.0% | 1% | +6.7% |
| 10 | NORTHERN TRUST CORP | 571,080 | $10.4M | 0.0% | 0.9% | +27.1% |
| 11 | BANK OF AMERICA CORP /DE/ | 510,325 | $9.3M | 0.0% | 0.8% | -1.2% |
| 12 | Nuveen, LLC | 471,947 | $8.6M | 0.0% | 0.8% | -41.4% |
| 13 | Sixth Street Partners Management Company, L.P.NEW | 464,034 | $8.5M | 1.5% | 0.8% | new |
| 14 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 464,034 | $8.5M | 0.0% | 0.8% | +7.2% |
| 15 | CITADEL ADVISORS LLC | 397,484 | $7.2M | 0.0% | 0.6% | +57.2% |
| 16 | DEUTSCHE BANK AG\ | 382,840 | $7.0M | 0.0% | 0.6% | +4.1% |
| 17 | VANGUARD FIDUCIARY TRUST CO | 363,136 | $6.6M | 0.0% | 0.6% | +5.9% |
| 18 | MILLENNIUM MANAGEMENT LLC | 346,232 | $6.3M | 0.0% | 0.6% | -0.1% |
| 19 | Connor, Clark & Lunn Investment Management Ltd. | 292,500 | $5.3M | 0.0% | 0.5% | +1.2% |
| 20 | JPMORGAN CHASE & CO | 282,631 | $5.2M | 0.0% | 0.5% | -4.9% |
| 21 | TWO SIGMA INVESTMENTS, LP | 272,581 | $5.0M | 0.0% | 0.4% | -47.8% |
| 22 | UBS Group AG | 248,627 | $4.5M | 0.0% | 0.4% | +22.8% |
| 23 | FMR LLC | 240,115 | $4.4M | 0.0% | 0.4% | +3220.2% |
| 24 | ADAGE CAPITAL PARTNERS GP, L.L.C.NEW | 238,000 | $4.3M | 0.0% | 0.4% | new |
| 25 | MOORE CAPITAL MANAGEMENT, LP | 189,946 | $3.5M | 0.1% | 0.3% | +79.3% |
Source: SEC Form 13F-HR filings (institutional managers over $100M in US-listed positions). 13Fs disclose long positions only, up to 45 days after quarter end; each manager's latest filed quarter is shown per row and dollar values are the manager's filed marks. Aggregates labeled "2026 filers" count only managers whose latest book is a 2026 quarter. Related: valuation · options positioning · supply chain. Research, not investment advice.